Lisata Therapeutics
LSTA
25 hedge funds and large institutions have $2.39M invested in Lisata Therapeutics in 2017 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 3 closing their positions.
75% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 4
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
4% more funds holding
Funds holding: 24 → 25 (+1)
0.06% more ownership
Funds ownership: 0.4% → 0.45% (+0.06%)
5% less capital invested
Capital invested by funds: $2.5M → $2.39M (-$114K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TFO
Tarbox Family Office
Newport Beach,
California
|
+$455K |
| 2 |
BlackRock
New York
|
+$83.2K |
| 3 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$61.7K |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
+$47.1K |
| 5 |
Renaissance Technologies
New York
|
+$41K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VKH
Virtu KCG Holdings
New York
|
-$183K |
| 2 |
Morgan Stanley
New York
|
-$16.5K |
| 3 |
Wells Fargo
San Francisco,
California
|
-$10K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$3.74K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$2.05K |
LSTA Hedge Fund Activity: Q2 2017 in Review
25 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Lisata Therapeutics (LSTA) for Q2 2017, worth a combined $2.39M — down 4.6% from $2.5M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new LSTA positions and 3 closed out — a net gain of 1 holder — while 7 added to existing stakes and 4 trimmed.
The largest buyer was Tarbox Family Office, opening a new position worth an estimated $455K. The largest seller was Virtu KCG Holdings, exiting entirely with an estimated $183K sold.
- 25 institutional investors held Lisata Therapeutics (LSTA) as of Q2 2017, up from 24 in Q1 2017.
- Funds reported $2.39M of Lisata Therapeutics stock for Q2 2017, down 4.6% quarter-over-quarter.
- 4 funds opened new Lisata Therapeutics positions in Q2 2017 and 3 closed out, a net change of +1 holder.
- The largest Lisata Therapeutics buyer in Q2 2017 was Tarbox Family Office, an estimated $455K added.
- The largest Lisata Therapeutics seller in Q2 2017 was Virtu KCG Holdings, an estimated $183K sold.
Based on aggregated 13F filings for Q2 2017.